Verdiva Bio’s once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences.
The post Metabolic Meds Startup Verdiva Launches With $410M and a Weekly Oral GLP-1 Drug appeared first on MedCity News.
